MONOKLONAL ANTITANACHALAR: ALZGEYMER KASALLIGINI DAVOLASHDAGI YANGI DAVR
Keywords:
Alzgeymer kasalligi, monoklonal antitanachalar, lekanemab, donanemab, beta-amiloid, ARIA.Abstract
Lekanemab va donanemab kabi miyadagi beta-amiloidni nishonga oluvchi monoklonal antitanachalar (MAT) kasallikning erta bosqichidagi bemorlarda kognitiv pasayishni sekinlashtirib, Alzgeymer kasalligini davolashda patogenetik (kasallikni o‘zgartiruvchi) yangi davrni boshlab berdi. AQSH oziq-ovqat va farmatsevtika idorasi (FDA) tomonidan tasdiqlangan ushbu terapiyalar immunoterapiya orqali amiloid g’umbaklarini tozalaydi va an’anaviy simptomatik dori vositalaridan farqli o‘laroq, yangicha yondashuvni taklif etadi. Biroq, ular miya shishishi yoki qon quyilishi (ARIA) kabi xavflar bilan birga kechadi.
References
Jacob, K. (2014). DSM-5 va demensiya: Tafsilotlar va nozik jihatlar. Hindiston psixiatriya jurnali.
Zhong, S., et al. (2025). 1990-yildan 2021-yilgacha 204 mamlakat va hududda demensiyaning global, mintaqaviy va milliy yuklamasi. Medicine.
Lane, K. A., Hardy, J., & Schott, J. M. (2018). Alzgeymer kasalligi. Yevropa nevrologiya jurnali.
Lobo, A., et al. (2000). Yevropada demensiya va uning asosiy turlarining tarqalishi: Populyatsiyaga asoslangan kohort tadqiqoti. Neurology, 54(11).
Tonegawa-Kuji, R., et al. (2025). Alzgeymer kasalligida beta-amiloidga yo‘naltirilgan passiv immunoterapiyalarning samaradorligi va xavfsizligi: Tizimli tahlil va meta-analiz. PLoS Medicine.
Van Dyck, C. H., et al. (2023). Erta bosqichdagi Alzgeymer kasalligida Lekanemab. The New England Journal of Medicine (NEJM), 388, 9-21.
Mintun, M. A., et al. (2021). Erta bosqichdagi Alzgeymer kasalligida Donanemab. The New England Journal of Medicine (NEJM), 384, 1691-1704.
Huang, Y., & Mucke, L. (2012). Alzgeymer mexanizmlari va terapevtik strategiyalar. Cell, 148(6), 1204-1222.
Sims, J. R., et al. (2023). Erta simptomatik Alzgeymer kasalligida Donanemab: TRAILBLAZER-ALZ 2 randomizatsiyalangan klinik sinovi. JAMA, 330(6), 512-527.
Sperling, R., et al. (2012). Bapineuzumab bilan davolangan Alzgeymer bemorlarida amiloid bilan bog‘liq vizuallashtirish anomaliyalari (ARIA): Retrospektiv tahlil. The Lancet Neurology, 11(3), 241-249.
Rabinovici, G., et al. (2025). Donanemab: To‘g‘ri foydalanish bo‘yicha tavsiyalar. Alzgeymer kasalligining oldini olish jurnali.
Boustani, M., et al. (2024). AQSHda erta simptomatik Alzgeymer uchun Donanemab bilan cheklangan muddatli davolashning iqtisodiy jihatdan oqlangan narxini baholash. Neurology and Therapy.
Rashad, A., et al. (2022). Alzgeymer kasalligi uchun Donanemab: Klinik sinovlarning tizimli tahlili. Healthcare, 10(11).
Weller, J., & Budson, A. (2018). Alzgeymer kasalligi tashxisi va davolash bo‘yicha zamonaviy tushunchalar. F1000Research.
Paczynski, M., et al. (2025). Ixtisoslashtirilgan xotira klinikasida Lekanemab bilan davolash. JAMA Neurology.
Cummings, J., et al. (2016). Alzgeymer kasalligida dori vositalarini ishlab chiqish: 2025-yilga borar yo‘l. Alzheimer’s Research & Therapy.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in IQRO — Scientific Methodological Journal are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Authors retain copyright and grant the journal the right of first publication.
Users may read, download, copy, distribute, print, search, or link to the full texts of articles, provided that the original authors and the journal are properly cited.
Published materials may be used, distributed, and reproduced in any medium, provided that the original work is properly cited.



Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo